Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rocky ascent

Novacea Inc. ended its Phase III trial of Asentar calcitriol for advanced prostate cancer last week after seeing a higher death rate in the Asentar arm, leaving the fate of the company's lead program uncertain. While the data are still blinded and a full analysis is likely to take months, the company believes it will be able to continue developing the

Read the full 618 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers